Floatz logo

AVOLVE

Lower Urinary Tract Symptoms

CHU de Quebec-Universite LavalSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Lower Urinary Tract Symptoms cohort.

Asset / SponsorPhaseRating
TESTOSTERONE UNDECYLATE
University of Florence
Phase 4BB
Meperidine
Taha Uçar
Phase 4BB
DICLOFENAC
Taha Uçar
Phase 4BB
Casodex
Alessa Therapeutics Inc.
Phase 2B
TAMOXIFEN
CHU de Quebec-Universite Laval
Phase 2B

View all 9 →

Same molecule, other indications

AVOLVE is also rated in:

prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
benign prostatic hyperplasiaDormant
BB
Indicative ·
68 / 100
View asset →
erectile dysfunctionDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →